We therefore sought to characterize HDAC9 expression in human B-cell lymphomas and establish whether aberrant expression can drive B-cell lymphoma in a genetically engineered mouse (GEM) model. Here, HDAC9 is linked to B-cell non-Hodgkin lymphoma.